Drug
Daratumumab
Daratumumab: highest development phase Post-Market, developed by Johnson & Johnson. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Johnson & Johnson
Trials
| Drug | Phase | Indication |
|---|---|---|
| Daratumumab NCT03768960 | Post-Market | Multiple Myeloma |
Latest
No recent events.
Follow Daratumumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.